Crispr Therapeut Stock Price, News & Analysis

CRISPR Therapeutics (Nasdaq: CRSP) announced participation in three key investor conferences in April 2022. These include the 21st Annual Needham Virtual Healthcare Conference on April 12 at 12:45 PM ET, the Canaccord Genuity Horizons in Oncology Virtual Conference on April 14 at 1:00 PM ET, and the 14th Kempen Life Sciences Conference in Amsterdam on April 20 at 3:30 PM CET. Live webcasts will be accessible on the company's website, with a 14-day replay available post-event.

CRISPR Therapeutics focuses on gene-based medicines for serious diseases using its innovative CRISPR/Cas9 technology.

CRISPR Therapeutics (Nasdaq: CRSP) will present an e-poster at the AACR 2022 Annual Meeting from April 8-13, 2022, highlighting its innovative cancer immunotherapy research. The presentation titled “CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells” is set for April 8, 2022. This research emphasizes the potential of CRISPR/Cas9 technology in advancing cancer treatments. As a leader in gene editing, CRISPR Therapeutics aims to develop transformative therapies for serious diseases, collaborating with major firms like Bayer and Vertex Pharmaceuticals.

CRISPR Therapeutics (Nasdaq: CRSP) has announced its participation in several investor conferences in March 2022. The schedules are as follows:

• Cowen 42nd Annual Health Care Conference on March 7 at 10:30 a.m. ET.
• Barclays Global Healthcare Conference on March 17 at 10:15 a.m. ET.
• Oppenheimer 32nd Annual Healthcare Conference on March 24 at 11:00 a.m. ET.

Live webcasts will be available on the company's website, with replays accessible for 14 days post-event.

CRISPR Therapeutics (Nasdaq: CRSP) reported a productive 2021, advancing its gene-editing therapies. More than 70 patients have been dosed with CTX001 for beta thalassemia and sickle cell disease, with regulatory submissions expected in late 2022. The company initiated the pivotal trial for CTX110 targeting B-cell malignancies, expecting further data this year. Financially, total revenue surged to $913.1 million from $0.5 million YoY, driven by Vertex collaborations. However, net loss widened to $141.2 million in Q4 2021, emphasizing the costs of R&D investments.

CRISPR Therapeutics (Nasdaq: CRSP) announced that its senior management team will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 p.m. ET. The event will be accessible via a live webcast on the company’s Investors section of its website. Following the event, a replay will be available for 14 days. CRISPR Therapeutics focuses on developing gene-based medicines using CRISPR/Cas9 technology to address serious diseases, with collaborations alongside industry leaders like Bayer and Vertex Pharmaceuticals.

CRISPR Therapeutics announced the first patient has been dosed in a Phase 1 clinical trial for VCTX210, a gene-edited, stem-cell therapy aimed at treating type 1 diabetes. Developed in partnership with ViaCyte, VCTX210 is designed to produce insulin while evading immune rejection. The trial will assess safety, tolerability, and immune evasion capabilities. If successful, VCTX210 could provide a transformative treatment option for diabetes patients without the need for immunosuppression.

CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two virtual investor conferences in December 2021. The first event is the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 12:35 p.m. ET. The second is the Piper Sandler 33rd Annual Healthcare Conference on December 2, 2021, at 1:00 p.m. ET. Webcast access will be available on CRISPR's website, with replays archived for 14 days post-event. CRISPR is focused on developing transformative gene-based medicines using its CRISPR/Cas9 platform.

CRISPR Therapeutics (Nasdaq: CRSP) announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110™, its allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. This designation highlights the promising clinical data and aims to expedite drug development and review processes. CTX110 is being evaluated in the CARBON trial for safety and efficacy. The RMAT designation facilitates discussions with the FDA and potential accelerated approval, emphasizing the transformative potential of CTX110 for patients with hematological malignancies.

CRISPR Therapeutics and ViaCyte have received approval from Health Canada for their Clinical Trial Application (CTA) for VCTX210, a gene-edited therapy aimed at treating type 1 diabetes (T1D). This therapy promises to be immune-evasive and stem cell-derived. Patient enrollment is anticipated to begin by the end of this year. The Phase 1 trial will evaluate VCTX210's safety, tolerability, and immune evasion. This milestone marks a significant step in developing gene-edited stem cell therapies for diabetes.